Izabela Laczmanska

Dr. Izabela Laczmanska


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SSStanislaw Supplitt
Stanislaw Supplitt
Paweł Andrzej KarpińskiPaweł Andrzej Karpiński
Paweł Andrzej Karpiński
MSMaria M. Sasiadek
Maria M. Sasiadek
IŁIzabela Łaczmańska
Izabela Łaczmańska
Over the last decades, transcriptome profiling emerged as one of the most powerful approaches in oncology, providing prognostic and predictive utility for cancer management. The development of novel technologies, such as revolutionary next-generation sequencing, enables the identification of cancer biomarkers, gene signatures, and their aberrant expression affecting oncogenesis, as well as the discovery of molecular targets for anticancer therapies. Transcriptomics contribute to a change in the holistic understanding of cancer, from histopathological and organic to molecular classifications, opening a more personalized perspective for tumor diagnostics and therapy. The further advancement on transcriptome profiling may allow standardization and cost reduction of its analysis, which will be the next step for transcriptomics to become a canon of contemporary cancer medicine.

11 May 2011 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
JGJustyna Gil
Justyna Gil
DRDave Ramsey
Dave Ramsey
ASAgnieszka Stembalska
Agnieszka Stembalska
Paweł Andrzej KarpińskiPaweł Andrzej Karpiński
Paweł Andrzej Karpiński
KPKarolina A. Pesz
Karolina A. Pesz
MSMaria M. Sasiadek
Maria M. Sasiadek

6 December 2011 in Acta Biochimica Polonica
Verified
Journal Article
Open access
PDF file
IŁIzabela Łaczmańska
Izabela Łaczmańska
MSMaria M. Sasiadek
Maria M. Sasiadek
Phosphorylation and dephosphorylation processes catalyzed by numerous kinases and phosphorylases are essential for cell homeostasis and may lead to disturbances in a variety of vital cellular pathways, such as cell proliferation and differentiation, and thus to complex diseases including cancer. As over 80 % of all oncogenes encode protein tyrosine kinases (PTKs), protein tyrosine phosphatases (PTPs), which can reverse the effects of tyrosine kinases, are very important tumor suppressors. Alterations in tyrosine kinase and phosphatase genes including point mutations, changes in epigenetic regulation, as well as chromosomal aberrations involving regions critical to these genes, are frequently observed in a variety of cancers. Colorectal cancer (CRC) is one of the most common cancers in humans. CRCs occur in a familial (about 15 % of all cases), hereditary (about 5%) and sporadic (almost 75-80 %) form. As genetic-environmental interrelations play an important role in the susceptibility to sporadic forms of CRCs, many studies are focused on genetic alterations in such tumors. Mutational analysis of the tyrosine phosphatome in CRCs has identified somatic mutations in PTPRG, PTPRT, PTPN3, PTPN13 and PTPN14. The majority of these mutations result in a loss of protein function. Also, alterations in the expression of these genes, such as decreased expression of PTPRR, PTPRO, PTPRG and PTPRD, mediated by epigenetic mechanisms have been observed in a variety of tumors. Since cancer is a social and global problem, there will be a growing number of studies on alterations in the candidate cancer genes, including protein kinases and phosphatases, to determine the origin, biology and potential pathways for targeted anticancer therapy.

25 October 2012 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
IŁIzabela Łaczmańska
Izabela Łaczmańska
Paweł Andrzej KarpińskiPaweł Andrzej Karpiński
Paweł Andrzej Karpiński
MBMarek Bebenek
Marek Bebenek
TSTomasz Sedziak
Tomasz Sedziak
DRDavid Ramsey
David Ramsey
MSMaria M. Sasiadek
Maria M. Sasiadek

1 June 2010 in Cancer Epidemiology
Verified
Journal Article
Closed access
Paweł Andrzej KarpińskiPaweł Andrzej Karpiński
Paweł Andrzej Karpiński
AMAleksander Myszka
Aleksander Myszka
DRDavid Ramsey
David Ramsey
Blazej MisiakBlazej Misiak
Blazej Misiak
JGJustyna Gil
Justyna Gil
MSMaria M. Sasiadek
Maria M. Sasiadek

7 September 2014 in Tumor Biology
Verified
Journal Article
Open access
PDF file
IŁIzabela Łaczmańska
Izabela Łaczmańska
LLLukasz Laczmanski
Lukasz Laczmanski
MBMarek Bebenek
Marek Bebenek
Paweł Andrzej KarpińskiPaweł Andrzej Karpiński
Paweł Andrzej Karpiński
HCHalina Czemarmazowicz
Halina Czemarmazowicz
MSMaria M. Sasiadek
Maria M. Sasiadek
The protective effect of vitamin D against several cancers including colorectal cancer is modulated by the vitamin D receptor (VDR) and its ligand, the active form of vitamin D. VDR response has been found to play a role in various genes encoding proteins involved in crucial cellular pathways. Single nucleotide polymorphisms (SNPs) of the VDR gene that modulate its activity are located in the promoter region, exons 2–9, and their vicinity and also in the 3′UTR region. Some of them have been previously studied in relation to cancer susceptibility and prognosis. The aim of our study was to investigate four polymorphisms, BsmI, ApaI, TaqI, and FokI, of the VDR gene in Polish patients with sporadic colorectal cancer and to evaluate their association with susceptibility to cancer. We found a significant association between the BsmI genotype and cancer (individuals with the bb genotype are more susceptible to cancer compared to those with other genotypes, p = 0.025, Fisher’s exact test for 2 × 2 table). Also, the TT genotype at TaqI and the AA genotype at ApaI are correlated with a higher risk of cancer (p = 0.00071 and p = 1.0 × 10−5, respectively). We found relatively strong linkage disequilibrium between the TaqI and ApaI loci (T with A and t with a, respectively). Both of these loci are associated with cancer. We do not observe any such association for the FokI polymorphism. In conclusion, a small modification in VDR expression may play a role in such a multipathway process as tumorigenesis.